{"id":38524,"date":"2016-07-04T00:00:00","date_gmt":"2016-07-03T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/"},"modified":"2020-11-16T16:20:26","modified_gmt":"2020-11-16T15:20:26","slug":"avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/","title":{"rendered":"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco"},"content":{"rendered":"<p>El ensayo, un estudio multic\u00e9ntrico en doble ciego y controlado por placebo, ha sido dise\u00f1ado para confirmar la seguridad, la tolerancia y la eficacia del nuevo f\u00e1rmaco y la<em> biotech<\/em> espera poder iniciarlo a finales de este a\u00f1o en diferentes ciudades del Estado espa\u00f1ol.\u00a0<\/p>\n<p>\u00abEl AVX-012 tiene el potencial de mejorar significativamente los signos y s\u00edntomas del s\u00edndrome de ojo seco, debido a su acci\u00f3n selectiva sobre la temperatura y la humedad que detecta las neuronas en la c\u00f3rnea, participando, por lo tanto, en la regulaci\u00f3n de la producci\u00f3n basal de l\u00e1grimas con el fin de estabilizar la pel\u00edcula lagrimal. La nueva mol\u00e9cula tambi\u00e9n podr\u00eda aportar algunos efectos analg\u00e9sicos que reducen el malestar ocular asociado con el s\u00edndrome del ojo seco\u00bb, explica Patrick Tresserras, fundador y consejero delegado de Avizorex Pharma.<\/p>\n<p>El S\u00edndrome de Ojo seco (SOS) es una enfermedad multifactorial de las l\u00e1grimas y superficie ocular que causa s\u00edntomas de malestar, inestabilidad y osmolaridad de la pel\u00edcula lagrimal, alteraciones visuales e inflamaci\u00f3n de la superficie ocular con el riesgo potencial de da\u00f1arla. La prevalencia reportada en los EE.UU., Australia y Europa es de un 5-15%; 25% en Canad\u00e1, y 30-50% en Asia, y es m\u00e1s com\u00fan en personas de origen asi\u00e1tico e hispano, y en las mujeres, especialmente postmenop\u00e1usicas (Fuente: Gayton, 2009. EME \/ 450332\/2012, 2012).<\/p>\n<p>\u00abActualmente hay muy pocas opciones terap\u00e9uticas eficaces para el manejo de los millones de personas afectadas en todo el mundo. Su tratamiento es principalmente sintom\u00e1tico y, hoy por hoy, hay muy pocos f\u00e1rmacos autorizados. Como consecuencia, esta enfermedad es una de las indicaciones de mayor crecimiento en oftalmolog\u00eda. Se prev\u00e9 que el mercado de productos para combatirla llegar\u00e1 a los\u00a0mil millones de d\u00f3lares en 2024\u00bb, comenta Tresserras.<\/p>\n<p>Avizorex Pharma, fundada en 2013 en Alicante y con oficinas en el Parc Cient\u00edfic\u00a0de Barcelona, centra su actividad en el desarrollo de nuevos tratamientos para el manejo del S\u00edndrome del Ojo Seco (SOS), a partir del trabajo de investigaci\u00f3n del neurocient\u00edfico Carlos Belmonte, catedr\u00e1tico de Fisiolog\u00eda de la Universidad Miguel Hern\u00e1ndez (<a href=\"http:\/\/www.umh.es\/\" target=\"_blank\" rel=\"noopener noreferrer\">UMH<\/a>) y fundador del Instituto de Neurociencias (<a href=\"http:\/\/in.umh.es\/es\/default.aspx\" target=\"_blank\" rel=\"noopener noreferrer\">IN<\/a>) de Alicante, un centro mixto de la UMH y del Consejo Superior de Investigaciones Cient\u00edficas (CSIC). Los resultados de su investigaci\u00f3n \u2013publicados a la prestigiosa revista Nature Medicine en 2010 (<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21076394\" target=\"_blank\" rel=\"noopener noreferrer\">doi:10.1038\/nm.2264<\/a>)\u2013 demostraron que la estimulaci\u00f3n farmacol\u00f3gica de la prote\u00edna a la que se dirige AVX-012 aumenta la secreci\u00f3n lagrimal fisiol\u00f3gica de forma natural y, por lo tanto, reduce la sequedad ocular.<\/p>\n<p>A finales de 2014, Avizorex cerr\u00f3 una ronda de financiaci\u00f3n por valor de 2,5 millones de euros, liderada por <a href=\"http:\/\/www.inveready.com\/es\" target=\"_blank\" rel=\"noopener noreferrer\">Inveready Technology Investment Group<\/a>, a trav\u00e9s de su fondo especializado en biotecnolog\u00eda Inveready Innvierte Biotech II, que inyect\u00f3 800.000 euros en la compa\u00f1\u00eda. La biofarmac\u00e8utica destinar\u00e1 los recursos obtenidos al avance en el desarrollo cl\u00ednico del f\u00e1rmaco.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0\u2022\u00a0<a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/noticies\/-\/noticia\/not_avizorex-pharma-obte-la-patent-als-eua-del-seu-tractament-contra-la-sindrome-d-ull-sec?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DAVIZOREX%26_cercador_WAR_empleatsempresesportlet_tab%3D0&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DAVIZOREX%26_cercador_WAR_empleatsempresesportlet_tab%3D0\">Noticia relacionada [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotecnol\u00f3gica <a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_006370&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3Davizorex%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">Avizorex Pharma<\/a> \u2013presente en el Parc Cient\u00edfic de Barcelona (PCB) y dedicada al desarrollo biofarmac\u00e9utico en el campo de la oftalmolog\u00eda\u2013 acaba de presentar la solicitud para iniciar un ensayo cl\u00ednico de Fase I\/ II del candidato a f\u00e1rmaco AVX-012, un <em>first-in-class<\/em> para combatir el S\u00edndrome de Ojo Seco (SOS) de grado leve a moderado.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":24610,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-38524","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La biotecnol\u00f3gica Avizorex Pharma \u2013presente en el Parc Cient\u00edfic de Barcelona (PCB) y dedicada al desarrollo biofarmac\u00e9utico en el campo de la oftalmolog\u00eda\u2013 acaba de presentar la solicitud para iniciar un ensayo cl\u00ednico de Fase I\/ II del candidato a f\u00e1rmaco AVX-012, un first-in-class para combatir el S\u00edndrome de Ojo Seco (SOS) de grado leve a moderado. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-03T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:20:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16049215325fa928bcaed78.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"676\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco\",\"datePublished\":\"2016-07-03T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:20:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/\"},\"wordCount\":531,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16049215325fa928bcaed78.jpeg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/\",\"name\":\"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16049215325fa928bcaed78.jpeg\",\"datePublished\":\"2016-07-03T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:20:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16049215325fa928bcaed78.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16049215325fa928bcaed78.jpeg\",\"width\":1024,\"height\":676},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/","og_locale":"es_ES","og_type":"article","og_title":"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco - Parc Cient\u00edfic de Barcelona","og_description":"La biotecnol\u00f3gica Avizorex Pharma \u2013presente en el Parc Cient\u00edfic de Barcelona (PCB) y dedicada al desarrollo biofarmac\u00e9utico en el campo de la oftalmolog\u00eda\u2013 acaba de presentar la solicitud para iniciar un ensayo cl\u00ednico de Fase I\/ II del candidato a f\u00e1rmaco AVX-012, un first-in-class para combatir el S\u00edndrome de Ojo Seco (SOS) de grado leve a moderado. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2016-07-03T23:00:00+00:00","article_modified_time":"2020-11-16T15:20:26+00:00","og_image":[{"width":1024,"height":676,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16049215325fa928bcaed78.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco","datePublished":"2016-07-03T23:00:00+00:00","dateModified":"2020-11-16T15:20:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/"},"wordCount":531,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16049215325fa928bcaed78.jpeg","articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/","url":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/","name":"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16049215325fa928bcaed78.jpeg","datePublished":"2016-07-03T23:00:00+00:00","dateModified":"2020-11-16T15:20:26+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16049215325fa928bcaed78.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16049215325fa928bcaed78.jpeg","width":1024,"height":676},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/avizorex-pharma-presenta-la-solicitud-para-iniciar-el-ensayo-clinico-de-su-farmaco-contra-el-sindrome-de-ojo-seco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Avizorex Pharma presenta la solicitud para iniciar el ensayo cl\u00ednico de su f\u00e1rmaco contra el s\u00edndrome de ojo seco"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=38524"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38524\/revisions"}],"predecessor-version":[{"id":44647,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38524\/revisions\/44647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/24610"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=38524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=38524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=38524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}